Today: 9 June 2026
Browse Category

NASDAQ:UNH 26 September 2025 - 6 February 2026

UnitedHealth stock slips after hours — here’s what could move UNH next

UnitedHealth stock slips after hours — here’s what could move UNH next

UnitedHealth shares fell 2.7% to $268.55 Thursday, with little change after hours, as investors reacted to Medicare Advantage reimbursement proposals. The Centers for Medicare & Medicaid Services set a Feb. 25 comment deadline and will announce final 2027 rates by April 6. UnitedHealth projected 2026 revenue above $439 billion, down from 2025 estimates. CEO Tim Noel called the proposed rate “disappointing.”
6 February 2026
·
Dow Jones today: Apple, Cisco lift the index as Fed decision and Big Tech earnings loom

Dow Jones today: Apple, Cisco lift the index as Fed decision and Big Tech earnings loom

The Dow Jones rose 0.6% to 49,403 Monday afternoon, led by Apple and Cisco, while UnitedHealth and 3M lagged. Gold and silver hit new records as the dollar weakened. The Federal Reserve begins a two-day meeting Tuesday, with rates expected to hold steady. Investors await earnings from major tech firms and the Fed’s decision Wednesday.
26 January 2026
·········
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Plus Therapeutics’ CNSide Diagnostics signed a national agreement with UnitedHealthcare to cover its CNSide tumor cell test, effective Sept. 15, potentially reaching over 51 million members. PSTV shares surged about 60% premarket on Sept. 25 after the news. CNSide’s Houston lab secured CLIA accreditation the prior week. Plus Therapeutics also received $1.9 million in non-dilutive funding from CPRIT on Sept. 22.
26 September 2025
···

Stock Market Today

  • ASX 200 Volatility Surges Amid Global Macro Swings on June 9, 2026
    June 9, 2026, 9:10 AM EDT. The ASX 200 index saw heightened volatility on June 9, 2026, plunging 134 points (-1.5%) before rebounding 100 points to trade 10 points lower at 8615 by 3:30 pm AEST. The sharp fall responded to Friday's heavy Wall Street losses triggered by a strong U.S. non-farm payroll report, which shifted expectations for the first Federal Reserve rate hike to late 2026. The rebound followed a drop in U.S. crude oil prices below $90 and improved U.S. equity futures, alongside optimism from a potential Israel-Iran ceasefire brokered with former President Trump's intervention. Domestic support emerged after National Australia Bank's Chief Economist expressed no expectation of further Reserve Bank of Australia rate hikes, citing soft GDP and weak business and consumer confidence signaling the economy has 'lost momentum.'

Latest articles

AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

9 June 2026
Grab shares hovered near $3.33 in pre-market trading after unveiling a new Singapore merchant programme and Taiwan partner commitments, as investors weigh growth initiatives against regulatory hurdles and consumer spending pressure; the stock’s muted move reflects ongoing uncertainty around its proposed foodpanda Taiwan acquisition and potential margin impacts from promotions.
Go toTop